MarrieRAElliottLMarriottJ, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology2014; 83: 929–937.
2.
WinkelmannALoebermannMReisingerEC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol2016; 12(4): 217–233.
3.
LunaGAlpingPBurmanJ, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol2019; 77: 3365.
4.
YeroushalmiSMaloniHCostelloK, et al. Telemedicine and multiple sclerosis: A comprehensive literature review. J Telemed Telecare. Epub ahead of print 1May2019. DOI: 10.1177/1357633X19840097.
5.
SormaniMP.An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. Epub ahead print 30April2020. DOI: 10.1016/s1474-4422(20)30147.
6.
WuCChenXCaiY, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Epub ahead of print 13Mach2020. DOI: 10.1001/jamainternmed.2020.0994.
7.
WangBLiRLuZ, et al. Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging2020; 12: 6049–6057.
8.
WijnandsJMAZhuFKingwellE, et al. Disease-modifying drugs for multiple sclerosis and infection risk: A cohort study. J Neurol Neurosurg Psychiatry2018; 89(10): 1050–1056.
9.
ShiYWangYShaoC, et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ2020; 27(5): 1451–1454.
10.
LebrunCVukusicS. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Mult Scler Relat Disord2019; 31: 173–188.
